LI
MNTA

Leap Investments’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Leap Investments’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-34,708
Closed -$685K – 670
2019
Q4 		$685K Buy
+34,708
New +$555K 0.32% 97

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Leap Investments's MNTA Position: Q1 2020 in Review

Leap Investments sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 34,708 shares — an estimated $685K sold.

Leap Investments first reported a position in MNTA in Q4 2019 and held it in 1 quarter. The position peaked at $685K in Q4 2019. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

  • Leap Investments reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Leap Investments sold 34,708 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $685K.
  • Leap Investments first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Leap Investments's Momenta Pharmaceuticals, Inc. position peaked at $685K in Q4 2019.
  • 199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.